"...Does this distinguished medical biotech researcher's connection with Toralgen (Dr.Rajagopalan) work at cross purposes with BioVaxys's approach to a better vaccine delivery system? Or is his connection with both companies now to be considered complementary? Are both companies now doing compatible research with a possible M&A connection sometime in the future?
"...Dr. Rajagopalan was Senior Director of Formulation Development at IMV, Inc., where he developed DPX-based vaccines to treat breast, ovarian, bladder and hard to reach cancers; and DPX-based RSV, Anthrax, ZIKA, Ebola, Tuberculosis and SARS infectious disease vaccines, as well as VLP-encapsulated DPX vaccines to treat Malaria and RSV infections. He also developed the DPX formulations for SurMAGE and KRAS/BRAS antigens to treat bladder and colorectal cancers, and formulation technology to deliver multiple peptides (up to 25 neoantigens) in a single DPX formulation for personalized cancer treatment, and an emulsion technology to co-deliver both small molecules chemotherapeutics and antibodies together for cancer treatments. In addition, Dr. Rajagopalan established that DPX technology can be used as a thermostable platform for vaccines with the inclusion of right additives (sugars and biodegradable polymers). Dr. Rajagopalan holds multiple patents to treat cancer and infectious diseases using DPX technology for the delivery of peptides, proteins, nucleic acids and small molecules. Dr. Rajagopalan currently works for Toralgen Inc., as VP Formulation/Manufacturing and Scientific Development, overseeing the formulation development and CMC activities for the oral delivery of GLP-1 peptides and mAbs..."
https://stockhouse.com/news/press-releases/2024/10/08/biovaxys-engages-dr-rajkannan-rajagopalan-as-vaccine-formulations-advisor Toralgen's primary objective seems to be the eventual replacement of vaccinations with an easily assimilable oral pill or capsule to uptake the necessary drugs into the diseased human organism. This is an early stage company with a lot of needed trials yet to do be done!
Perhaps this may also be a better longer term pill delivery platform like BioVaxys's DPX platform is the better one for injections to help foster the cure for human disease? And even though oral vaccines may never completely replace the need for injecting vaccines, perhaps they may someday play a significantly larger part in the manner of quickly getting any needed drugs to the source of a problem?
Certainly where larger amounts of drug need to be introduced more directly to a target than a small pill could possibly do, BioVaxys's DPX delivery platform seems destined to remain superior!
[And as yet, there are no guarantees that any pill form may deliver drugs in any amount efficaciously to all forms of human disease!]
https://toralgen.com/ "IMPROVING DRUG DELIVERY
NANOPARTICLE TECHNOLOGY
Effective and Efficient Oral Therapeutics from Pill to Circulation
Our unique poly-bile nanoparticle platform holds promise to replace injections and eliminate the challenges of oral delivery in a breakthrough nanopill technology. The pill protects drugs, including biologics, through the stomach and intestines while retaining bioactivity. At the intestinal wall, the nanoparticles are taken into the body and enter circulation, where the drug is released.
Working in collaboration with pharma partners and thought leaders, Toralgen creates novel formulations of proven therapeutics for metabolic and autoimmune diseases replacing cumbersome and often painful injections with a simple and easy to swallow pill. Our proprietary nanopill technology is composed of bile acids that naturally occur in the gut of humans and other mammals. The unmodified terminal ends of our poly bile molecule decorate the outside of our nanoparticles leading to significant uptake as the body seeks to recycle the bile through the enterohepatic path. This allows the nanoparticles to be taken into the body along with whatever drug is loaded inside of them. The technology is capable of encapsulating small molecules, peptides, proteins, and monoclonal antibodies for delivery. We are also in active development of formulations to deliver antigens and immunomodulators orally." Can both of these companies offer the best solution for the cure of disease? Wouldn't pharmaceutical companies want to wait for this kind of question to be answered before considering taking out a license with your company?
Have you approached any of the big pharmaceutical companies (with the exception of Zoetis with their potential cattle control fertility program) about your better vaccination delivery system licensing opportunity that might apply to humans? Does your drug delivery system (even with your present patents) still need to go through some significant series of trials before any big pharmaceutical company would accept such a license from you for human vaccines?
Why did you give the main licensing opportunity for fertility control to SpayVac as opposed to Zoetis when the latter company is the bigger one? Has Zoetis put the BioVaxys license on some back burner without any date fixed date for the commencement of any production? If so, would you have agreed to such a licensing deal? Could this deal be cancelled if they do not choose to proceed with production any time soon? Could you give this remaining license opportunity to SpayVac with whom you seem more intent on bringing such a product to market?
Or are you keeping your options open and if SpayVac doesn't proceed in a more timely way, would you offer Zoetis all of the license? Are both of these two agreements open with termination clauses already set up legally in the deal?
Perhaps BioVaxys might consider partnering with Toralgen to maximize both companies' future possibility of success? You have stated in your latest video that the total number of shares outstanding are not too relevant in a junior biotech's future pricing strategy using biotechs trading on the Nasdaq exchange as a perfect example. If so, why not make a fair exchange share swap deal with the private start-up entity Toralgen and place the combined entity on the Nasdaq for trading to make both companies prosper sooner?
https://youtu.be/W-8dXkHexmc?si=kbhGxKHh8QphxlnI Toralgen is presently 'seed' funded by a hopeful investment community. They may be on the right track with their better oral medicine as well as BioVaxys seems to be with their superior vaccination process!
Wouldn't their 'seed' money investors like to be invested with a company actively trading on one or more stock exchanges in Canada and the USA? And America is a much bigger market with a lot more money involved in any company's process of growth!
Perhaps Dr.Rajagopalan's immediate connection with both companies might help make this kind of junior biotech M&A happen sooner than later?..." The end.
[url=jpassin@biovaxys.com][/url]
https://www.biovaxys.com/ https://spayvac.com/ https://www2.zoetis.ca/ It's just an idea! But the best technology, always marches ahead!
And astute money managers watch and wait for the best moment to pounce!
Who's been buying up most of our shares?
All the best,Java